CFM
NMRA icon

Catalyst Funds Management’s Neumora Therapeutics NMRA Stock Holding History

Catalyst Funds Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,300
Closed -$64.9K – 807
2026
Q1 		$64.9K Buy
33,300
+3,700
+13% +$9.59K 0.01% 523
2025
Q4 		$53K Hold
29,600
– – 0.01% 324
2025
Q3 		$53.9K Sell
29,600
-9,800
-25% -$15.8K 0.01% 476
2025
Q2 		$28.9K Buy
+39,400
New +$29.8K 0.01% 406

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Catalyst Funds Management's NMRA Position: Q2 2026 in Review

Catalyst Funds Management sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 33,300 shares — an estimated $64.9K sold.

Catalyst Funds Management first reported a position in NMRA in Q2 2025 and held it in 4 quarters. The position peaked at $64.9K in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Catalyst Funds Management reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 33,300 Neumora Therapeutics shares in Q2 2026, an estimated $64.9K.
  • Catalyst Funds Management first reported a position in Neumora Therapeutics in Q2 2025 and held it in 4 quarters.
  • Catalyst Funds Management's Neumora Therapeutics position peaked at $64.9K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.